AVERAGE WAIT

Wait times are an average and provided for informational purposes only. What does this mean?

Small Interfering RNA Can Reduce LDL Cholesterol

Small Interfering RNA Can Reduce LDL Cholesterol

ALN-PCS is safe and seems effective for reducing LDL cholesterol from baseline, relative to placebo

THURSDAY, Oct. 3 (HealthDay News) -- A small interfering RNA (ALN-PCS) that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) is safe and seems effective for lowering low-density lipoprotein (LDL) cholesterol, according to a phase 1 study published online Oct. 3 in The Lancet.

Kevin Fitzgerald, Ph.D., from Alnylam Pharmaceuticals in Cambridge, Mass., and colleagues conducted a placebo-controlled, phase 1 dose-escalation study involving 32 healthy adult volunteers with serum LDL cholesterol of 3.0 mmol/L or more. Participants were randomized to receive one dose of intravenous ALN-PCS (24 participants; doses ranging from 0.015 to 0.400 mg/kg) or placebo (eight participants).

The researchers found that a similar proportion of participants experienced a treatment-emergent adverse effect in the ALN-PCS and placebo groups (79 versus 88 percent). ALN-PCS was rapidly distributed and, across the dose range tested, the peak concentration and area under the curve increased in a roughly dose-proportionate manner. Treatment with 0.400 mg/kg correlated with a mean 70 percent reduction in circulating PCSK9 plasma protein and, relative to placebo, with a mean 40 percent decrease in LDL cholesterol from baseline.

"Our results suggest that inhibition of PCSK9 synthesis by RNA interference provides a potentially safe mechanism to reduce LDL cholesterol concentration in healthy individuals with raised cholesterol," the authors write.

The study was funded by Alnylam Pharmaceuticals, the developer of ALN-PCS.

Abstract (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61914-5/abstract )Full Text (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61914-5/fulltext )Editorial (subscription or payment may be required) (http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(13)61910-8/fulltext )